PDCD1 and cancer: Additionally, monotherapies of PD-1 inhibitors are associated with higher overall survival rates than monotherapies of other immune checkpoint inhibitors such as ipilimumab (anti-CTLA-4 monoclonal antibody) and BRAF/MEK inhibitors; also, they can be used for the treatment of a variety of cancers [54, 55].